FIG 3.

Survival outcome defined by detection of cell-free methylated RASSF1A (RASSF1A-M) from plasma and rhabdomyosarcoma-specific RNA in blood and bone marrow at diagnosis. (A and B) EFS and OS of 56 patients on the basis of the absence or presence of rhabdomyosarcoma-specific RNA (RNA-negative and RNA-positive, respectively) combined with RASSF1A-M status. Shown below each plot is the number of patients at each time point and 5-year survival with the 95% CI. OS, overall survival; EFS, event-free survival.